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ABSTRACT
Introduction: Medication therapy for type 2
diabetes has become increasingly complex, and
there are few reliable data on the current state of
clinical practice. We report treatment pathways
and associated costs of medication therapy for
people with type 2 diabetes in the UK, their
variability and changes over time.
Methods: Prescription and biomarker data for
7159 people with type 2 diabetes were extracted
from the GoDARTS cohort study, covering the
period 1989–2013. Average follow-up was
10 years. Individuals were prescribed on average
2.4 (SD: 1.2) drugs with average annual costs of
£241. We calculated summary statistics for first-
and second-line therapies. Linear regression
models were used to estimate associations
between therapy characteristics and baseline
patient characteristics.
Results: Average time from diagnosis to first
prescription was 3 years (SD: 4.0 years). Almost
all first-line therapy (98%) was monotherapy,
with average annual cost of £83 (SD: £204) for
3.8 (SD: 3.5) years. Second-line therapy was
initiated in 73% of all individuals, at an average
annual cost of £219 (SD: £305). Therapies
involving insulin were markedly more expen-
sive than other common therapies. Baseline
HbA1c was unrelated to future therapy costs,
but higher average HbA1c levels over time were
associated with higher costs.
Conclusions: Medication therapy has under-
gone substantial changes during the period
covered in this study. For example, therapy is
initiated earlier and is less expensive than in the
past. The data provided in this study will prove
useful for future modelling studies, e.g. of
stratified treatment approaches.
Keywords: Costs; First-line therapy;
Medication therapy; Second-line therapy;
Therapy initiation; Type 2 diabetes; UK
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INTRODUCTION
Stratified treatment approaches for type 2 dia-
betes appear promising, since there is evidence
of underlying heterogeneity in type 2 diabetes
[1, 2] and many classes of oral anti-diabetes
drugs with different mechanisms of action are
available. Ongoing research efforts, such as the
Mastermind study [3], aim to develop and
evaluate stratified treatments. However, evalu-
ating the benefits of stratified treatment over
current clinical practice is made difficult by the
increasingly complex sequencing and combi-
nations of diabetes therapies under current
clinical practice [4]. While guidelines suggest
that metformin monotherapy should be used as
the initial medication therapy, there is no clear
guidance on the choice of other drug classes for
later therapy lines or in persons where met-
formin is not tolerated or contraindicated [5, 6].
Algorithms [6] and case studies [7] have been
developed to support individualised treatment
decisions. However, the current state of clinical
practice is not clear, with surprisingly little
reliable information. Previous health economic
studies mainly focused on the costs of diabetes
[8–13] or national prescription trends [14–18].
The few studies that have investigated the costs,
timing and duration of individual therapies
[19–21] have mostly focused on first-line
therapy.
This article reports contemporary treatment
pathways (i.e. the timing, duration and drug
types prescribed in first- and second-line ther-
apy) and associated costs for medication ther-
apy of type 2 diabetes in the UK. We describe
how treatment pathways and costs vary over
time and across demographic subgroups.
METHODS
Study Population
We used data from the Genetics of Diabetes
Audit and Research Tayside (GoDARTS) cohort
study [22, 23]. The study included individuals
with physician-diagnosed type 2 diabetes in
Tayside and Fife, Scotland. Participants were
recruited from primary care, secondary care
diabetes clinics as well as primary care registers
between 1998 and 2012 [24, 25]. Data were
collected prospectively, and patient records
were linked to the DARTS databases [26] to
obtain retrospective data on prescriptions, bio-
chemistry and phenotypes.
This study focused on prescriptions of
anti-diabetes drugs for patients with type 2
diabetes. We excluded patients diagnosed
before age 35 years, those who received insulin
less than a year after diagnosis as well as indi-
viduals who received anti-diabetes drugs within
6 months of their first recorded prescription of
any drug. Moreover, we excluded individuals
with missing or inconsistent data on date of
diagnosis. Finally, we excluded one patient who
received gliquidone. A detailed description of
our data cleaning and processing procedures is
provided in the appendix.
Our final sample consisted of 19,269 obser-
vations for 7159 individuals. For this study,
observations refer to prescription blocks, i.e.
prescriptions of anti-diabetes drugs as well as
repeat prescriptions of the same drug. For each
of these blocks, we observed the date of the first
and last prescription, the average daily dose and
baseline demographic data. The costs were
derived from the Prescription Cost Analysis
England 2014 [27], and we linked data on drugs
to average annual HbA1c levels from the GoD-
ARTS study.
Table S.1 in the appendix shows the charac-
teristics of the study cohort. Participants were
recruited between 1998 and 2012. About half of
the participants were diagnosed before 1998.
On average, participants had been diagnosed
with type 2 diabetes 7 years before recruitment
to the study and at an average age of 59.2 years.
The data cover on average 10 years of follow-up,
in which participants have been prescribed two
different drugs on average with annual costs
amounting to £241. Average body mass index
(BMI) at the time of the first prescription was
31.5 kg/m2, and 64% of the participants had
smoked in the past. Average HbA1c levels at
diagnosis were 60 mmol/mol (7.6%).
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Statistical Methods
We investigated frequency, timing, duration
and costs of first- and second-line drug therapy
as well as cost profiles over time and by different
subgroups. In this analysis, we define a therapy
line as any combination of drugs taken at the
same time. A change of therapy occurs when-
ever an additional drug is prescribed or treat-
ment with a drug is discontinued. Summary
statistics are presented as means and standard
deviations. Median values and interquartile
ranges are presented in the appendix (Tables S.4
and S.5). R version 3.2 was used to process the
data.
We conducted two-sample t-tests to test the
significance of differences between subgroups.
As a sensitivity analysis, we conducted Wil-
coxon rank-sum tests to test whether observa-
tions from different subgroups were drawn from
the same distribution. Linear regression models
with robust standard errors were used to esti-
mate associations between baseline characteris-
tics and therapy characteristics for first- and
second-line therapy. We conducted several
sensitivity analyses to account for potential
sources of bias. We estimated Tobit models
censored at zero to account for the non-nega-
tivity of the outcome variables (appendix
Table S.6). We estimated Cox and Weibull
regression models in a survival analysis to
account for censoring (appendix Table S.8).
Finally, we re-estimated our models using only
individuals with at least 5 and at most 15 years
of follow-up to account for the limited duration
of follow-up for individuals diagnosed from the
year 2000 onwards (Appendix Table S.9). All
statistical analyses were conducted in Stata
version 14.1.
Ethics Compliance
Approval for the GoDARTS study was granted
by the East of Scotland Regional Ethics Com-
mittee (09/21402/44). This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Descriptive Statistics for First-
and Second-Line Therapy
Table S.2 (Appendix) shows drug combinations
for first-line therapy. In about 60% of cases
metformin monotherapy was used as first-line
therapy, as recommended in the guidelines,
followed by sulphonylurea (34%). These fig-
ures vary substantially over time. Among people
diagnosed before the year 2000, 89% received
either metformin or sulphonylurea monother-
apy, and 7% were prescribed insulin
monotherapy. In contrast, among people diag-
nosed after the year 2000 (and after the intro-
duction of guidelines recommending
metformin as first-line therapy), 97% of all
individuals were prescribed metformin or
sulphonylurea monotherapy.
With the exception of insulin therapy, all
common therapies cost less than £1000 for the
entire duration of the drug therapy. Insulin is
by far the most expensive first-line therapy with
treatment costs of about £975 per year for the
drug alone (excluding equipment such as test
strips).
Only 7.3% of all individuals received their
first prescription at the time of diagnosis.
Average time to first-line therapy was 3 years,
and this therapy was continued, on average, for
4 years. Table 1 provides these numbers for the
whole sample as well as for different subgroups.
The analysis by year of diagnosis indicates that
the proportion of people commencing therapy
at time of diagnosis has increased over time,
while time to first-line drug therapy has fallen
to 1.9 years for individuals diagnosed after the
year 2000 compared with 4.5 years for those
diagnosed before 2000 (difference = -2.6 years,
p\0.001). However, it should be noted that
fewer years of follow-up were available for peo-
ple diagnosed in later years.
Annual therapy costs for first-line therapy
were also lower for individuals diagnosed after
2000 (£51.6 vs. £120.8, difference = -£69.2,
p\0.001). We find that annual therapy costs
were lower for obese people (BMI C 30 kg/m2)
(£68.5 vs. £88.1, difference = -£19.6,
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Table 1 Duration and costs of first-line therapy
Therapy at diagnosis (%) Time to therapy (years) Annual cost of therapy (£) Duration of therapy (years)
Overall sample (n = 7159) 7.25 3.05 ± 4.02 83.11 ± 203.68 3.81 ± 3.55
A. Gender
Men (n = 3953) 7.03 3.2 ± 4.15 78.59 ± 191.58 3.77 ± 3.47
Women (n = 3206) 7.52 2.86 ± 3.85 88.68 ± 217.57 3.87 ± 3.65
B. Smoking status
Smoked (n = 4098) 7.98 2.76 ± 3.7 68.25 ± 155.93 3.66 ± 3.37
C. BMI
BMI\30 (n = 2825) 4.99 3.57 ± 4.34 88.08 ± 225.99 4.01 ± 3.65
BMI C30 (n = 3362) 6.37 2.76 ± 3.47 68.48 ± 152.54 3.52 ± 3.09
D. Year of diagnosis
Before 2000 (n = 3259) 4.45 4.46 ± 5.04 120.82 ± 279.46 4.32 ± 4.21
From 2000 onwards
(n = 3900)
9.59 1.86 ± 2.31 51.59 ± 93.39 3.39 ± 2.82
E. Age at diagnosis
\50 (n = 1406) 9.59 4.2 ± 5.55 141.57 ± 310.87 3.61 ± 3.94
50–54 (n = 942) 7.01 3.39 ± 4.18 100.74 ± 240.71 3.76 ± 3.7
55–59 (n = 1209) 6.70 3.11 ± 3.77 73.66 ± 168.14 3.64 ± 3.31
60–64 (n = 1231) 7.80 2.74 ± 3.49 68.04 ± 165.87 3.92 ± 3.47
65–69 (n = 1098) 8.56 2.54 ± 3.17 64.87 ± 140.15 3.92 ± 3.59
C70 (n = 1273) 8.25 2.21 ± 2.72 44.77 ± 85.9 4.04 ± 3.23
F. Initial HbA1c levels
1st quartile (n = 1496) 4.48 4.43 ± 4.31 68.11 ± 181.86 4.06 ± 3.42
2nd quartile (n = 1425) 4.91 2.94 ± 3.11 50.25 ± 97.64 3.84 ± 3.03
3rd quartile (n = 1438) 6.82 1.92 ± 2.77 56.9 ± 127.84 3.64 ± 3.03
4th quartile (n = 1453) 14.18 1.18 ± 2.5 56.55 ± 88.46 3.18 ± 3.18
G. Average HbA1c levels
1st quartile (n = 1453) 6.13 3.45 ± 3.99 51.13 ± 100.21 4.95 ± 3.8
2nd quartile (n = 1453) 6.54 2.68 ± 3.35 48.08 ± 82.44 4.26 ± 3.25
3rd quartile (n = 1453) 8.33 2.41 ± 3.31 59.22 ± 145.2 3.22 ± 2.62
4th quartile (n = 1453) 9.36 1.99 ± 3.05 73.84 ± 171.02 2.3 ± 2.17
Source: GoDARTS, Prescription Cost Analysis England 2014. Column 1 gives the percentage of people that received their first prescription at the time of
their diagnosis. Initial HbA1c quartiles in mmol/mol: [16, 46); [46, 55); [55, 69); [69, 178). Average HbA1c quartiles in mmol/mol: [36, 53); [53, 58);
[58, 65); [65, 112). Initial HbA1c quartiles in %: [3.6, 6.4); [6.4, 7.2); [7.2, 8.5); [8.5, 18.4). Average HbA1c quartiles in %: [5.4, 7.0); [7.0, 7.5); [7.5,
8.1); [8.1, 12.4)
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Table 2 Duration and costs of second-line therapy
Second-line
therapy
observed
(%)
Therapy
substitution
(%)
Gap
‡90 days
(%)
Gap between
1st- and
2nd-line
therapies (years)
Duration
of therapy
Annual cost
therapy
Overall (n = 5254) 73.39 15.32 7.74 1.71 ± 2.29 3.12 ± 3.07 186.53 ± 264.51
A. Gender
Men (n = 2890) 73.11 14.15 7.06 1.7 ± 2.28 3.15 ± 2.99 181.86 ± 256.77
Women (n = 2364) 73.74 16.75 8.58 1.72 ± 2.31 3.08 ± 3.17 192.23 ± 273.63
B. Smoking status
Smoked (n = 3042) 74.23 14.40 7.22 1.74 ± 2.33 3.11 ± 3.03 177.25 ± 255.55
C. BMI
BMI\30 (n = 1953) 69.13 17.15 8.25 1.7 ± 2.34 3.06 ± 3.05 184.9 ± 275.22
BMI C30 (n = 2468) 73.41 12.56 5.98 1.33 ± 1.87 2.9 ± 2.79 185.36 ± 248.29
D. Year of diagnosis
1989–1999
(n = 2697)
82.76 18.28 10.83 1.94 ± 2.57 3.68 ± 3.54 198.8 ± 286.84
2000–2013
(n = 2557)
65.56 12.20 5.15 1.35 ± 1.71 2.52 ± 2.34 173.58 ± 238.08
E. Age at diagnosis
\50 (n = 1185) 84.28 16.37 10.81 1.97 ± 2.09 3 ± 3.06 231.96 ± 308.9
50–54 (n = 759) 80.57 11.86 5.94 1.57 ± 2.26 3.11 ± 2.87 205.06 ± 282.76
55–59 (n = 924) 76.43 14.50 8.11 1.94 ± 2.71 3.2 ± 3.1 168.37 ± 218.25
60–64 (n = 917) 74.49 15.59 7.55 1.5 ± 2.28 3.39 ± 3.28 174.44 ± 261.84
65–69 (n = 765) 69.67 14.77 6.83 1.65 ± 2.27 3.24 ± 3.17 169.16 ± 241.9
C70 (n = 704) 55.30 18.61 6.28 1.46 ± 2.17 2.7 ± 2.83 148.5 ± 232.77
F. Initial HbA1c levels
1st quartile (n = 1074) 71.79 17.50 10.09 2.36 ± 2.77 3.11 ± 3.12 168.28 ± 245.96
2nd quartile
(n = 1024)
71.86 17.29 8.07 1.48 ± 2.04 2.87 ± 2.84 178.83 ± 262.06
3rd quartile
(n = 1180)
82.06 14.41 7.44 1.37 ± 1.78 3.1 ± 2.92 177.76 ± 241
4th quartile
(n = 1270)
87.41 9.29 5.23 1.52 ± 2.14 3.31 ± 3.04 161.13 ± 222.71
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p\0.001). In addition, these people received
their first prescription on average 10 months
earlier than non-obese people.
First-line therapy was initiated earlier for
older people (e.g. 2.21 years for those over 70
compared with 4.2 years for individuals below
50; difference = 1.99 years, p\0.001), and
annual therapy costs were lower for older indi-
viduals as well (£44.77 for those over 70 vs.
£141.57 for those under 50, differ-
ence = -£79.13, p\0.001).
Finally, higher HbA1c values (both initial as
well as average values) were associated with
earlier therapy initiation, and high average
HbA1c values were associated with a shorter
duration of first-line therapy.
Table S.3 in the Appendix presents data for
second-line drug therapy. Only 15% of the
individuals received a monotherapy as their
second-line drug treatment. A combination of
metformin and sulphonylurea was the single
most common second-line therapy, accounting
for 62% of all second-line therapies. The
majority of second-line treatments were rela-
tively inexpensive.
A summary for subgroups of the population
is provided in Table 2. Here, we note that in the
later (2000–2013) time period more second-line
therapies involved adding an additional drug
rather than substituting a drug. This may reflect
the larger number of therapy options available
in later years. Again, we find that therapy costs
decreased over time (£198.8 vs. £173.6, differ-
ence = £25.2, p\0.001), although the rank-
sum test indicates that the differences in dis-
tributions are not significant (p = 0.0593). In
contrast to the results for first-line therapies, the
costs for second-line therapies are approxi-
mately equal for obese and non-obese people;
however, the rank-sum tests indicate statisti-
cally significant differences in the underlying
distributions (p\0.001). A higher age at diag-
nosis is associated with lower costs for sec-
ond-line therapy (difference between people
over 70 and those under 50 = -£57.05,
p\0.001). Finally, higher average HbA1c values
were associated with higher annual costs (dif-
ference between 1st and 4th quartile = £50.38,
p\0.05) and a shorter duration of second-line
therapy (difference = -0.39 years, p\0.001).
Table 2 continued
Second-line
therapy
observed
(%)
Therapy
substitution
(%)
Gap
‡90 days
(%)
Gap between
1st- and
2nd-line
therapies (years)
Duration
of therapy
Annual cost
therapy
G. Average HbA1c levels
1st quartile (n = 715) 49.21 24.90 9.02 2.22 ± 2.93 3.13 ± 3.09 165 ± 257.07
2nd quartile
(n = 1103)
75.91 13.24 6.33 1.71 ± 2.32 3.58 ± 3.3 149.16 ± 202.73
3rd quartile
(n = 1336)
91.95 11.38 7.09 1.55 ± 1.93 3.34 ± 3.04 170.83 ± 241.26
4th quartile
(n = 1394)
95.94 12.70 8.47 1.34 ± 1.52 2.5 ± 2.49 191.91 ± 261.83
Source: GoDARTS, Prescription Cost Analysis England 2014. Column 1 gives the percentage of individuals for whom a
switch in therapy is observed. Column 2 shows the percentage of people for whom the 2nd-line therapy consisted of a
substitution of drugs instead of the addition of a new drug. Initial HbA1c quartiles in mmol/mol: [16, 46); [46, 55); [55,
69); [69, 178). Average HbA1c quartiles in mmol/mol: [36, 53); [53, 58); [58, 65); [65, 112). Initial HbA1c quartiles in %:
[3.6, 6.4); [6.4, 7.2); [7.2, 8.5); [8.5, 18.4). Average HbA1c quartiles in %: [5.4, 7.0); [7.0, 7.5); [7.5, 8.1); [8.1, 12.4)
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Table 3 Regression of therapy outcomes on baseline characteristics
Variable First-line therapy Second-line therapy
Time to therapy Duration Cost per day Duration Cost per day
Age at diagnosis (reference category:\50)
50–54 -152.446* 45.347 -0.008 -22.284 0.002
(63.006) (52.162) (0.023) (52.571) (0.039)
55–59 -205.008*** -15.278 -0.053** 22.598 -0.094**
(58.115) (48.195) (0.018) (51.838) (0.032)
60–64 -316.749*** 88.786 -0.049** 70.109 -0.061
(57.591) (51.290) (0.018) (54.678) (0.037)
64–69 -394.032*** -0.996 -0.051** 2.438 -0.052
(56.852) (53.088) (0.017) (57.118) (0.039)
[70 -396.952*** 82.913 -0.063*** -87.313 -0.140***
(54.526) (52.676) (0.018) (56.638) (0.039)
BMI between 25.00 and 29.99 kg/m2 -126.735 16.983 -0.012 98.779 -0.120**
(68.544) (58.996) (0.021) (60.080) (0.045)
BMI between 30.00 and 39.99 kg/m2 -273.037*** -51.281 -0.019 102.157 -0.099*
(66.671) (57.433) (0.021) (58.575) (0.045)
BMI over 40.00 kg/m2 -533.993*** -14.823 -0.009 -24.59 0.016
(76.372) (73.930) (0.027) (71.202) (0.056)
Women -66.725* 34.295 0.011 -17.542 -0.013
(30.481) (31.351) (0.009) (33.481) (0.022)
Smoking at baseline -76.338* -114.040*** 0.003 7.197 0.001
(32.655) (32.332) (0.010) (33.966) (0.023)
Diagnosis[2000 -793.356*** -376.393*** -0.052*** -447.346*** 0.006
(35.997) (35.443) (0.010) (35.990) (0.022)
Initial HbA1c levels (reference category: 1st quartile)
2nd quartile -342.326*** 89.083* -0.036* 46.745 0.027
(47.524) (43.797) (0.015) (47.975) (0.033)
3rd quartile -710.038*** 166.387*** -0.034* 177.645*** 0.027
(47.305) (45.493) (0.016) (48.326) (0.032)
4th quartile -942.402*** 171.061*** -0.034* 358.566*** -0.052
(48.313) (48.820) (0.017) (50.468) (0.031)
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Associations between Baseline
Characteristics and Therapy
Characteristics
Table 3 shows the results of linear regressions
exploring the association between baseline
characteristics and the timing, duration and
costs of first- and second-line therapies. Each
column shows the results from one regression
model. Since all covariates are binary indicators,
the point estimates should be interpreted as
differences from the specified reference group.
The constant gives the average for the overall
reference group. For example, the results in
column 1 should be interpreted as follows: The
average time to first-line therapy for a
non-smoking normal-weight man diagnosed
before age 50 and before the year 2000 with
both low initial and average HbA1c values was
2722 days or 7.5 years. For older individuals
first-line therapy is initiated earlier. For exam-
ple, for individuals aged 70 and above, therapy
is initiated 397 days earlier.
Overall, the results confirm that year of
diagnosis is significantly associated with time to
therapy, duration and costs. For people diag-
nosed after the year 2000, first-line therapy was
initiated on average 793 days (2.2 years) earlier
than for those diagnosed before 2000. While it
is important to note that fewer years of fol-
low-up are available for individuals diagnosed
later, sensitivity analyses addressing differences
in the length of follow-up confirm our conclu-
sions (see Appendix, Table S.8). The duration of
first-line therapy was on average 376 days
shorter for people diagnosed after 2000 when
compared with those diagnosed before the year
2000, i.e. second-line therapy was initiated
earlier. For second-line therapy, year of diag-
nosis was also significantly associated with a
shorter therapy duration. The results also show
that both higher initial and average HbA1c
values are associated with earlier commence-
ment of first-line therapy. For example, indi-
viduals within the third quartile of initial
HbA1c values start medication therapy on
Table 3 continued
Variable First-line therapy Second-line therapy
Time to therapy Duration Cost per day Duration Cost per day
Average HbA1c levels (reference category: 1st quartile)
2nd quartile -163.530*** -298.665*** -0.012 103.534 -0.038
(43.709) (49.185) (0.009) (54.530) (0.033)
3rd quartile -271.994*** -734.805*** 0.013 -22.667 0.014
(46.616) (47.834) (0.014) (52.417) (0.034)
4th quartile -374.481*** -1074.575*** 0.044** -327.883*** 0.058
(48.544) (50.016) (0.014) (52.361) (0.037)
Constant 2722.145*** 2042.405*** 0.247*** 1194.238*** 0.606***
(104.222) (83.145) (0.034) (79.370) (0.059)
N 5187 5187 5187 3929 3929
Source: GoDARTS, Prescription Cost Analysis England 2014. Time to therapy and duration of therapy in days. Costs are
given in £. Initial HbA1c quartiles in mmol/mol: [16, 46); [46, 55); [55, 69); [69, 178). Average HbA1c quartiles in
mmol/mol: [36, 53); [53, 58); [58, 65); [65, 112). Initial HbA1c quartiles in %: [3.6, 6.4); [6.4, 7.2); [7.2, 8.5); [8.5, 18.4).
Average HbA1c quartiles in %: [5.4, 7.0); [7.0, 7.5); [7.5, 8.1); [8.1, 12.4). The table shows regression coefficients from a
linear regression of therapy duration and costs on baseline characteristics. Robust standard errors are shown in parentheses.
*** p\0.001; ** p\0.01; * p\0.05
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average 710 days earlier than individuals within
the first quartile, and for those within the
fourth quartile therapy is initiated 942 days
(2.6 years) earlier than for those in the first
quartile. Interestingly, higher initial HbA1c
values are associated with longer first-line ther-
apy, while higher average HbA1c values are
associated with shorter first-line therapy.
We also considered interaction effects
between year of diagnosis and other baseline
characteristics (sex, BMI and smoking status, see
Table S.8 in the Appendix). The estimated
interaction effects were insignificant in most
models, with the exception of time to first-line
therapy.
Longitudinal Changes in Therapy Costs
We also investigated longitudinal changes in
costs of therapy over time. For each individual,
we aggregated costs of all drugs prescribed in
each year, as first-line, second-line or subse-
quent treatment, starting the first year at the
date of the first observed prescription. The
results are shown in Figs. 1 and 2 below.
The dots mark the average costs across all
individuals in a given year, and lines show 95%
confidence intervals around the means. Figure 1
shows that therapy costs steadily increased over
time from diagnosis, starting at less than £100
per year and increasing to slightly less than
£400 per year at 10 years after the start of ther-
apy. There were no major differences between
males and females. In contrast, therapy costs
were lower for obese compared to non-obese
people for the first 3 years after first prescrip-
tion, after which the pattern reversed. This is in
line with the findings in Tables 1 and 2. Average
annual therapy costs were generally lower for
people diagnosed after the year 2000.
Figure 2 shows the same data by age smoking
status, age at diagnosis and initial as well as
average HbA1c levels. Therapy costs for smok-
ing and non-smoking individuals are very sim-
ilar. A lower age at diagnosis is associated with
higher annual costs across all age categories.
Interestingly, the association between average
HbA1c levels and costs per year seems stronger
than the association between costs and initial
HbA1c levels. For initial HbA1c levels, only
individuals within the fourth quartile incurred
significantly higher costs than those in the
other three categories. In contrast, cost patterns
for all four quartiles of average HbA1c level
show a diverging pattern. Annual costs in the
10th year after therapy initiation are about £600
higher in the fourth quartile than in the first
quartile. This finding is confirmed in Figure S.1
in the Appendix, where we plotted average
annual costs over all years by HbA1c decile.
DISCUSSION
One of the main contributions of this article is
to describe patterns of medication therapy for
people with type 2 diabetes in the UK, including
data on timing and costs of therapies and their
associations with baseline characteristics of
individuals. Desai et al. [19] and Boccuzzi et al.
[20] provided similar data for the US, but they
investigated first-line therapy and not sec-
ond-line therapy.
Our data show that over the past 2 decades
drug therapy has become increasingly complex.
There were 16 different first-line therapies and
29 different second-line therapies recorded in
the data. Most of these therapy lines were very
similar in terms of duration and costs. Therapies
involving insulin were among the most expen-
sive treatments and cost on average more than
£1000 over the course of 3–4 years. This is in
line with earlier findings reported by Rathmann
et al. [16, 17] for Germany. Similarly, Bexelius
et al. [28] reported that annual costs doubled
after initiation of insulin therapy in a cohort of
Swedish patients.
We also find that treatment pathways and
costs have changed considerably over the past 2
decades: first-line therapy is initiated earlier
than it was for people diagnosed before 2000,
and individuals progress faster through therapy
lines. This is in contrast to the findings of Strain
et al. [29], who concluded that time to treat-
ment intensification has not changed signifi-
cantly since the 1990s. Interestingly, we also
found that in the first 3 years after diagnosis
annual therapy costs were lower for people
diagnosed after the year 2000 than for people
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diagnosed earlier. This likely reflects changing
guidelines for first-line therapy. However, our
results also indicated that considerable scope
remains for earlier therapy initiation.
There were some differences across demo-
graphic groups, e.g. obese individuals had on
average lower therapy costs during first-line
therapy than non-obese people. A possible
explanation for this finding might be that
therapy for obese individuals initially consists
of weight loss and exercise alongside less
expensive drugs, whereas non-obese people
might be more likely to receive insulin early on.
Indeed, the data showed that among people
Fig. 1 The dots mark the average cost per year following the
first observed prescription. The lines show 95% confidence
intervals. Measurements refer to completed years. Markers
are offset to improve readability. The upper left panel shows
the average profile for the whole sample. The upper right
graph shows separate trends formales and females. The lower
left figure shows data for people with a BMI above and below
30, and the lower right figure shows separate graphs for
people diagnosed before and after the year 2000. Source:
GoDARTS, Prescription Cost Analysis England 2014
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receiving insulin as first-line therapy (253
observations) only 35.9% had a BMI C 30 kg/
m2, whereas among those not receiving insulin
monotherapy (6906 observations) 54.9% were
obese. The difference (19%) was statistically
significant (p\0.001). However, this initial
difference vanishes after 3 years (Fig. 1). More-
over, medication therapy is initiated earlier in
Fig. 2 The dots mark average cost per year following the
first observed prescription. The lines show 95% confidence
intervals. Measurements refer to completed years. Markers
are offset to improve readability. The upper left panel shows
trends for smokers and non-smokers at baseline. The upper
right graph shows separate trends by age at diagnosis. The
lower left figure shows data by quartile of the initial HbA1c
values, and the lower right figure shows data by quartile of
the average HbA1c values. Initial HbA1c quartiles in
mmol/mol: [16, 46); [46, 55); [55, 69); [69, 178). Average
HbA1c quartiles in mmol/mol: [36, 53); [53, 58); [58,
65); [65, 112). Initial HbA1c quartiles in %: [3.6, 6.4);
[6.4, 7.2); [7.2, 8.5); [8.5, 18.4). Average HbA1c quartiles
in %: [5.4, 7.0); [7.0, 7.5); [7.5, 8.1); [8.1, 12.4). Source:
GoDARTS, Prescription Cost Analysis, England 2014
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obese people (Table 1), and therefore the life-
time costs of obese people could even be higher.
We also found that high average HbA1c
levels over the period of our study are associated
with up to four times higher costs than lower
HbA1c levels. This is likely because individuals
showing a poor response to their initial thera-
pies have their doses intensified and move on to
other drugs more rapidly than individuals
showing a good response. While Porath et al.
[30] reported that the impact of HbA1c on costs
was limited, our findings are in line with Ben-
nett et al. [31] and Fu et al. [32], who found that
increasing HbA1c levels and the lack of a gly-
caemic response, respectively, were predictors
of therapy initiation and escalation.
There are several limitations of our study.
First, it is based on a sample drawn entirely from
Tayside and Fife, Scotland, and so may not be
representative of prescription patterns or of
populations elsewhere, although there is no
reason to think these are systematically differ-
ent (apart from low representation of some
ethnic groups). Second, the data cannot be used
to accurately describe prescribing patterns and
costs before the 1990s, since very few people in
the cohort were diagnosed at that point. Simi-
larly, the duration of follow-up in some of our
analyses is necessarily limited. For example, our
data do not include any prescriptions of SGLT-2
inhibitors. Nevertheless, our findings show that
newer drugs (e.g. GLP-1 receptor agonists and
DPP4-inhibitors) are rarely prescribed in first- or
second-line therapy. We note also that indi-
viduals had to be alive at the time of their
inclusion into the cohort, and consequently
individuals with major adverse events shortly
after diagnosis might be under-represented in
the study. It is also possible that the estimates of
our regression analysis are biased because of
unobserved confounders (e.g. education,
comorbidities, etc.). However, this study does
not test any specific hypotheses, nor do we aim
to study causal effects. Instead, the focus is on
differences across easily identifiable subgroups
of people with type 2 diabetes. Therefore, we are
less concerned about confounding. We used
linear regression models to study associations
between baseline characteristics and therapy
outcomes, since linear models offer an intuitive
interpretation of the results. However, the
results could be affected by a number of issues.
Censoring of the data might mean that the
recorded duration of first- and second-line
therapy is underreported. We conducted a sur-
vival analysis to assess the sensitivity of our
results and found that our conclusions hold.
Moreover, our outcomes (costs and duration)
are non-negative, and therefore the assumption
of normally distributed standard errors in the
linear regression model might not hold. We
estimated Tobit regression models in a sensi-
tivity analysis and concluded that our main
findings are robust. Finally, our comparison of
individuals diagnosed before the year 2000 and
from the year 2000 onwards might be biased by
the limited duration of follow-up for individu-
als in the latter group. We assessed the sensi-
tivity of our results by restricting the sample to
individuals with a minimum of 5 and a maxi-
mum of 15 years of follow-up. This did not
affect our main conclusions.
The data reported in this study only include
anti-diabetes drugs. While anti-diabetes drugs
account for a small proportion of the overall
healthcare expenditures attributable to diabetes
[8], the costs of prescription medications (and
anti-diabetes drugs in particular) are a major
driver of increasing costs over time both in the
population [13] and for individual people [9].
There are some limitations to the dosage and
cost data in our study. Our data are based on
prescription encashment rather than actual
usage. This is particularly problematic for insu-
lin, since individuals can modify the dose as
part of their self-management. Moreover, our
data on insulin costs only include the drug itself
and not any other necessary equipment, e.g.
test strips. Consequently, the data on the costs
of insulin might be less accurate than for other
drugs. However, we argue that these limitations
most likely lead to an underestimation of the
costs of insulin therapy. We used prescription
cost data from 2014. On the one hand, this
means that we do not observe changes in costs
over time (e.g. changes in prescription patterns
for different types of insulins). On the other
hand, the figures reported in this study might
be more relevant for future modelling studies,
since they use current prices for drugs. Finally,
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we focused here on annualised HbA1c levels
and average doses. Some therapy approaches
could involve shorter-term fine-tuning of dose
intensification and therapy changes, but
understanding patterns of within-year changes
will require more complex methods and data
sets and are a task for future work.
CONCLUSIONS
Over the past 2 decades, medication therapy for
type 2 diabetes has undergone substantial
changes in the UK. Nevertheless, scope remains
for earlier therapy initiation and intensification.
The data presented in this study should prove
useful for future modelling studies.
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